12:00 AM
 | 
Jul 29, 2013
 |  BC Week In Review  |  Company News  |  Deals

Adimab, Biogen Idec, GlaxoSmithKline deal

In separate deals, Adimab granted non-exclusive licenses to Biogen Idec and GlaxoSmithKline to internalize Adimab's yeast-based antibody discovery platform to discover and optimize antibody-based therapeutics, including bispecific antibodies. Each partner will use the platform to identify antibodies in undisclosed therapeutic areas. Adimab said it is...

Read the full 203 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >